I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  LeGoff, Jérome ^a,b,c   Rousset, Dominique ^d,e   Abou Jaoudé, Georges ^d,e   Scemla, Anne ^b   Ribaud, Patricia ^b   Mercier Delarue, Séverine ^b,c   Caro, Valérie ^d   Enouf, Vincent ^d,e   Simon, François ^a,b,c   Molina, Jean Michel ^b   van der Werf, Sylvie ^a,d,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSERM   (France)

^d INSTITUT PASTEUR   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; HEMAGGLUTININ; OSELTAMIVIR; PREDNISOLONE; SUNITINIB; VALACICLOVIR; VIRUS SIALIDASE; VORICONAZOLE; ZANAMIVIR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BINDING AFFINITY; CASE REPORT; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE MUTATION; GENE SEQUENCE; GENERAL CONDITION DETERIORATION; GENETIC VARIABILITY; HUMAN; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LEUKEMIA RELAPSE; MALE; MEDICAL HISTORY; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; PHYSICAL EXAMINATION; REVERSE GENETICS; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL GENETICS; VIROGENESIS; VIRUS DETECTION; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS SHEDDING; VIRUS TITRATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; INFLUENZA A VIRUS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 84865281481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037095     Document Type: Article

References (46)

1. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG, (2006) Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 193: 760-764.
2. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
3. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
4. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307-317.
5. Abed Y, Goyette N, Boivin G, (2004) A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 9: 577-581.
6. Bloom JD, Gong LI, Baltimore D, (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
7. Aoki FY, Boivin G, Roberts N, (2007) Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 12: 603-616.
8. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, et al. (2009) Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 15: 552-560.
9. Moscona A, (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
10. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S, (2008) Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 4: e1000103.
11. Rameix-Welti MA, Munier S, le Gal S, Cuvelier F, Agou F, et al. (2011) Neuraminidase of 2007-2008 influeza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antiviral Therapy 16, in press.
12. Holmes EC, (2010) Virology. Helping the resistance. Science 328: 1243-1244.
13. WHO (2011) Global monitoring of antiviral resistance in currently circulating human viruses, november 2011. WER 45: 497-508.
14. Chen H, Cheung CL, Tai H, Zhao P, Chan JF, et al. (2009) Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 15: 1970-1972.
15. CDC (2011) Seasonal Influenza- Weekly report: influenza summary update- 2009-2010 influenza Season Summary.
16. Tramontana AR, George B, Hurt AC, Doyle JS, Langan K, et al. (2010) Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 16: 1068-1075.
17. Chan PA, Connell NT, Gabonay AM, Westley B, Larkin JM, et al. (2010) Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin Microbiol Infect.
18. Dulek DE, Williams JV, Creech CB, Schulert AK, Frangoul HA, et al. (2010) Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 50: 1493-1496.
19. Harvala H, Gunson R, Simmonds P, Hardie A, Bennett S, et al. (2010) The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009. Euro Surveill 15.
20. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, et al. (2011) H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerging infectious diseases 17: 653-660; quiz 765.
21. Da Dalt L, Calistri A, Chillemi C, Cusinato R, Franchin E, et al. (2010) Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir. Emerging infectious diseases 16: 1813-1815.
22. Moore C, Galiano M, Lackenby A, Abdelrahman T, Barnes R, et al. (2011) Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. The Journal of infectious diseases 203: 18-24.
23. Gaur AH, Bagga B, Barman S, Hayden R, Lamptey A, et al. (2010) Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. The New England journal of medicine 362: 88-89.
24. Esposito S, Molteni CG, Colombo C, Daleno C, Dacco V, et al. (2010) Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 48: 62-65.
25. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV, (2010) Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 51: 983-984.
26. van der Vries E, Stelma FF, Boucher CA, (2010) Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382.
27. Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, et al. (2011) Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerging infectious diseases 17: 1472-1474.
28. WHO (2009) WHO information for laboratory diagnosis of pandemic (H1N1) 2009 virus in humans- 23 november 2009.http://www.who.int/csr/resources/publications/swineflu/WHO_Diagnostic_RecommendationsH1N1_20090521.pdf. Accessed 2012 July 27.
29. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, et al. (2010) Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 54: 1102-1110.
30. de Wit E, Spronken MI, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. (2004) Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res 103: 155-161.
31. Rameix-Welti MA, Tomoiu A, Dos Santos Afonso E, van der Werf S, Naffakh N, (2009) Avian Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection. J Virol 83: 1320-1331.
32. Matrosovich M, Matrosovich T, Garten W, Klenk HD, (2006) New low-viscosity overlay medium for viral plaque assays. Virol J 3: 63.
33. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. Am J Hygiene 27: 493-497.
34. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, et al. (2006) Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 50: 3809-3815.
35. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG, (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178: 1257-1262.
36. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
37. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG, (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83: 10366-10373.
38. Hurt AC, Lowther S, Middleton D, Barr IG, (2010) Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res.
39. Baz M, Abed Y, McDonald J, Boivin G, (2006) Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43: 1555-1561.
40. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, et al. (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
41. Hurt AC, Holien JK, Barr IG, (2009) In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 53: 4433-4440.
42. CDC (2009) Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 58: 969-972.
43. Pizzorno A, Bouhy X, Abed Y, Boivin G, (2011) Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. The Journal of infectious diseases 203: 25-31.
44. Peng AW, Milleri S, Stein DS, (2000) Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrobial agents and chemotherapy 44: 1974-1976.
45. van der Vries E, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, et al. (2011) Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS pathogens 7: e1002276.
46. Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, et al. (2012) Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrobial agents and chemotherapy 56: 1208-1214.